COMP <GO>
RVMD vs MRK // EV/EBITDA & P/E VALUATION
Revolution Medicines Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RVMD 3
— MRK 11
■ METRIC PARITY
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 74.80% | -30.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 20.70% | -49.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.42% | -5.66 | MRK | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.30% | -17.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.10% | -15.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 1.30% | +14.10 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 56.9 | -8.11 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.92 | +0.15 | RVMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 18.4x | +15.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $361.02B | -$320.24B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | MRK REV | RVMD GROSS % | MRK GROSS % | RVMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$913.7M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$567.7M | $18.10B |
| FY 2023 | $11.6M | $60.12B | 44.0% | 44.0% | -$351.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
MRK // BETA 0.92